Onvansertib (NMS-P937, PCM-075, NMS1286937) is an orally potent, selective Polo-like Kinase 1 (PLK1) inhibitor with an IC50 value of 2 nM. 5000 times more selective than PLK2/PLK3. Onvansertib (NMS-P937) can induce mitotic cycle arrest and apoptosis in tumor cell lines and inhibit tumor growth. Phase 1.

 

Brand: BCM

 

Target: Apoptosis; PLK

 

Signaling Pathways: Apoptosis; Cell Cycle/Checkpoint

 

In Vitro: NMS-P937 shows a broad-spectrum antiproliferative activity against different solid tumor, leukemias and lymphomas cell lines. NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in A2780 cells.

 

Boiling Point: 757.8±70.0 °C(Predicted)

 

pKa: 14.29±0.10(Predicted)

 

Solubility: Soluble in DMSO; Soluble Ethanol. Insoluble in Water.

 

Isomeric SMILES: CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO  

 

InChIKey: QHLVBNKYJGBCQJ-UHFFFAOYSA-N  

 

InChI: InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31) 

 

Attribute
[CAS No.]	1034616-18-6
[Formula]	C24H27F3N8O3
[Molecular]	532.52
[Chem Name]	1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide
[Synonym]	NMS-P937; NMS1286937; Onvansertib
[Storage]	Keep in dark place. Sealed in dry, 2-8°C
[MDL No.]	MFCD26793840
[Form]	Solid

Goods Tag